Login to Your Account



Sepracor, GSK Enter $155M Deal Covering Global Lunesta Rights

By Jim Shrine


Wednesday, September 12, 2007
Sepracor Inc. entered a potential $155 million deal with GlaxoSmithKline plc covering its insomnia product Lunesta in Europe and elsewhere, about six weeks after it filed for European approval of the drug. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription